Theravance Biopharma (NASDAQ: TBPH) reported Q3 EPS of ($1.40), $0.04 better than the analyst estimate of ($1.44). Revenue for the quarter came in at $10.7 million versus the consensus estimate of $4.24 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.